- Home
- SPHR vs IMCR Comparison
SPHR vs IMCR Comparison
Compare SPHR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- IMCR
- Stock Information
- Founded
- SPHR 2020
- IMCR 2008
- Country
- SPHR United States
- IMCR United Kingdom
- Employees
- SPHR N/A
- IMCR N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPHR Consumer Discretionary
- IMCR Health Care
- Exchange
- SPHR Nasdaq
- IMCR Nasdaq
- Market Cap
- SPHR 1.7B
- IMCR 1.8B
- IPO Year
- SPHR N/A
- IMCR 2021
- Fundamental
- Price
- SPHR $60.26
- IMCR $34.42
- Analyst Decision
- SPHR Buy
- IMCR Buy
- Analyst Count
- SPHR 9
- IMCR 8
- Target Price
- SPHR $51.22
- IMCR $57.00
- AVG Volume (30 Days)
- SPHR 1.3M
- IMCR 275.9K
- Earning Date
- SPHR 11-11-2025
- IMCR 11-05-2025
- Dividend Yield
- SPHR N/A
- IMCR N/A
- EPS Growth
- SPHR N/A
- IMCR N/A
- EPS
- SPHR N/A
- IMCR N/A
- Revenue
- SPHR $1,040,932,000.00
- IMCR $356,145,000.00
- Revenue This Year
- SPHR $9.57
- IMCR $31.83
- Revenue Next Year
- SPHR $9.62
- IMCR $8.50
- P/E Ratio
- SPHR N/A
- IMCR N/A
- Revenue Growth
- SPHR 1.37
- IMCR 26.78
- 52 Week Low
- SPHR $23.89
- IMCR $23.15
- 52 Week High
- SPHR $61.28
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- SPHR 78.53
- IMCR 50.65
- Support Level
- SPHR $51.35
- IMCR $35.33
- Resistance Level
- SPHR $55.19
- IMCR $36.76
- Average True Range (ATR)
- SPHR 2.71
- IMCR 1.36
- MACD
- SPHR 1.45
- IMCR 0.16
- Stochastic Oscillator
- SPHR 94.46
- IMCR 40.47
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.